Elefsiniotis Ioannis S, Skounakis Michael, Vezali Elena, Pantazis Konstantinos D, Petrocheilou Aikaterini, Pirounaki Maria, Papatsibas George, Kontou-Kastellanou Chrysa, Moulakakis Antonios
Department of Internal Medicine, Hippokration Hospital of Athens, Carchidonos 9, A. Glyfada, GR-16562 Greece.
Eur J Gastroenterol Hepatol. 2006 May;18(5):525-30. doi: 10.1097/00042737-200605000-00012.
To evaluate the diagnostic value of serum procalcitonin levels in patients with acute or chronic liver disease, with or without bacterial infections and to correlate the results with the clinical outcome and the laboratory findings for these patients.
One hundred and six consecutive hospitalized patients with liver disease were evaluated for procalcitonin levels on admission. Fifteen of them (14.2%) had acute alcoholic hepatitis on cirrhotic background (group A), 20 (18.9%) had alcoholic cirrhosis without hepatitis and/or bacterial infection (group B), 16 (15.1%) had decompensated cirrhosis with proved bacterial infection (group C), 42 (39.6%) had uncomplicated viral hepatitis-related cirrhosis (group D) and 13 (12.3%) had acute icteric viral hepatitis (group E). Serum procalcitonin levels were measured using an immunoluminometric assay. Statistical analysis was based on Student's t-test and the non-parametric Kruskall-Wallis test (P<0.05).
Serum procalcitonin levels were significantly higher in cirrhotic patients with bacterial infection (9.80+/-16.80 ng/ml) than in those without bacterial infection (0.21+/-0.13 ng/ml, P=0.001), whereas they were within normal range (<0.5 ng/ml) in all patients with uncomplicated cirrhosis, irrespective of the cause of cirrhosis. Seven of 15 group A patients (46.2%) and 4/13 group E patients (30.8%), all of them cirrhotics, had procalcitonin levels higher than 0.5 ng/ml on admission, without established bacterial infection.
Serum procalcitonin levels remain below the threshold of 0.5 ng/ml in all patients with uncomplicated cirrhosis, irrespective of the cause of the disease, while they are significantly elevated when bacterial infection complicates the course of the disease. A significant proportion of patients with acute alcoholic hepatitis on a cirrhotic background as well as of patients with acute on chronic viral hepatitis, without bacterial infection, exhibit serum procalcitonin levels above 0.5 ng/ml, suggesting that this cut-off value is probably not enough to discriminate between patients with or without bacterial infection within these subgroups of patients with liver disease.
评估血清降钙素原水平在急慢性肝病患者(无论有无细菌感染)中的诊断价值,并将结果与这些患者的临床结局及实验室检查结果相关联。
对106例连续住院的肝病患者入院时的降钙素原水平进行评估。其中15例(14.2%)为肝硬化背景下的急性酒精性肝炎(A组),20例(18.9%)为无肝炎和/或细菌感染的酒精性肝硬化(B组),16例(15.1%)为已证实有细菌感染的失代偿期肝硬化(C组),42例(39.6%)为无并发症的病毒性肝炎相关肝硬化(D组),13例(12.3%)为急性黄疸型病毒性肝炎(E组)。采用免疫发光分析法测定血清降钙素原水平。统计分析基于学生t检验和非参数Kruskal-Wallis检验(P<0.05)。
有细菌感染的肝硬化患者血清降钙素原水平(9.80±16.80 ng/ml)显著高于无细菌感染的患者(0.21±0.13 ng/ml,P=0.001),而所有无并发症肝硬化患者(无论肝硬化病因如何)的血清降钙素原水平均在正常范围内(<0.5 ng/ml)。A组15例患者中有7例(46.2%)和E组13例患者中有4例(30.8%)(均为肝硬化患者)入院时降钙素原水平高于0.5 ng/ml,但未确诊有细菌感染。
所有无并发症肝硬化患者(无论病因如何)的血清降钙素原水平均低于0.5 ng/ml阈值,而当疾病过程中出现细菌感染时,该水平会显著升高。相当一部分肝硬化背景下的急性酒精性肝炎患者以及慢性病毒性肝炎急性发作患者(无细菌感染)的血清降钙素原水平高于0.5 ng/ml,这表明该临界值可能不足以区分这些肝病亚组中有或无细菌感染的患者。